Literature DB >> 6084981

Ribonuclease-sensitive ribosomal vaccines.

R Gonggrijp, A C Antonissen, J F van den Bosch, C P van Boven.   

Abstract

This paper presents an analysis of the protective properties of the components in ribonuclease (RNase)-sensitive ribosomal vaccines, in particular the ribonucleic acid (RNA). The protective activities in mice of purified ribosomes derived from Pseudomonas aeruginosa and from Listeria monocytogenes were compared. Both ribosomal vaccines had to be combined with the adjuvant dimethyldioctadecylammonium bromide (DDA) in order to be protective, and both lost their activity after RNase treatment. The ribosomal vaccines as well as RNA purified from the ribosomes induced non-specific protection. Intraperitoneal injection of RNA with DDA induced an influx of peritoneal cells. Furthermore, RNA with DDA activated macrophages as shown by, a.o., enhanced phagocytic activity and killing capacity for L. monocytogenes. The results suggest that the observed macrophage activation is probably T-cell-independent. With regard to the ribosomal vaccine of P. aeruginosa it is concluded that RNA also contributed to the protective activity by increasing the humoral response against suboptimal concentrations of contaminating cell surface antigens. In conclusion, it is proposed that ribosomal vaccines may be considered as a combination of a non-specific immunomodulator (RNA) with pathogen-specific cell surface antigens. This concept of ribosomal vaccines is discussed in relation to the literature concerning RNase-sensitive ribosomal vaccines.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6084981     DOI: 10.1007/bf02386239

Source DB:  PubMed          Journal:  Antonie Van Leeuwenhoek        ISSN: 0003-6072            Impact factor:   2.271


  27 in total

1.  Protection against Toxoplasma gondii in mice immunized with Toxoplasma cell fractions, RNA and synthetic polyribonucleotides.

Authors:  F G Araujo; J S Remington
Journal:  Immunology       Date:  1974-10       Impact factor: 7.397

2.  Evidence for O antigens as the antigenic determinants in "ribosomal" vaccines prepared from Salmonella.

Authors:  T K Eisenstein
Journal:  Infect Immun       Date:  1975-08       Impact factor: 3.441

3.  Biochemical and immunological properties of ribonucleic acid-rich extracts from Francisella tularensis.

Authors:  I I Andron LA; H T Eigelsbach
Journal:  Infect Immun       Date:  1975-07       Impact factor: 3.441

4.  Ribosomal vaccines. II. Specificity of the immune response to ribosomal ribonucleic acid and protein isolated from Salmonella typhimurium.

Authors:  W Johnson
Journal:  Infect Immun       Date:  1973-09       Impact factor: 3.441

5.  Effect of nonspecific stimulation on the defense mechanisms of inbred mice.

Authors:  S Medina; S I Vas; H G Robson
Journal:  J Immunol       Date:  1975-06       Impact factor: 5.422

6.  Immunogenic activity of a ribosomal fraction obtained from Pasteurella multocida.

Authors:  T Baba
Journal:  Infect Immun       Date:  1977-01       Impact factor: 3.441

7.  Protective activities of ribosomal ribonucleic acid and lipopolysaccharide of Pseudomonas aeruginosa: a comparative study.

Authors:  R Gonggrijp; W J Mullers; C P van Boven
Journal:  Antonie Van Leeuwenhoek       Date:  1983-06       Impact factor: 2.271

8.  Ribonuclease-sensitive ribosomal vaccine of Pseudomonas aeruginosa.

Authors:  R Gonggrijp; W J Mullers; P J Lemmens; C P van Boven
Journal:  Infect Immun       Date:  1980-01       Impact factor: 3.441

9.  Direct evidence for the involvement of capsular polysaccharide in the immunoprotective activity of Klebsiella pneumoniae ribosomal preparations.

Authors:  M M Riottot; J M Fournier; H Jouin
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

10.  Immunogenicity of Ribosomal Preparations from Yeast Cells of Histoplasma capsulatum.

Authors:  C Feit; R P Tewari
Journal:  Infect Immun       Date:  1974-11       Impact factor: 3.441

View more
  1 in total

1.  T-cell-independent macrophage activation in mice induced with rRNA from Listeria monocytogenes and dimethyldioctadecylammonium bromide.

Authors:  J F van den Bosch; I Y Kanis; A C Antonissen; W A Buurman; C P van Boven
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.